snk01
Cell therapyexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2019 (NCT03894579)
Timeline
Indications
Studied for
- Alzheimer Disease · Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Cognitive Dysfunction · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Genes, erbB-2 · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Neurodegenerative Diseases · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Psoriasis · Phase 1
- Sarcoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Unspecified targetOTHER
Enhanced NK cells
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650287 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07228078 | Phase 2 | Jun 30, 2025 | NKGen Biotech, Inc. |
| NCT06189963 | Phase 1/Phase 2 (Phase 2) | Nov 21, 2023 | NKGen Biotech, Inc. |
| NCT05099549 | Phase 1/Phase 2 (Phase 2) | Nov 3, 2021 | Affimed GmbH, NKGen Biotech, Inc. |
| NCT04872634 | Phase 1/Phase 2 (Phase 2) | Jul 8, 2021 | NKMAX Co., Ltd. |
| NCT04464967 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2021 | NKMAX Co., Ltd. |
| NCT04678453 | Phase 1 | Dec 31, 2020 | Hospital Angeles Tijuana, NKMAX Co., Ltd. |
| NCT03894579 | Phase 1 | May 31, 2019 | Hospital Angeles Tijuana, NKMAX Co., Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NKMAX Co., Ltd. | For profit | 4 | 4 | 2 | 2019 |
| NKGen Biotech, Inc. | For profit | 3 | 3 | 1 | 2021 |
| Hospital Angeles Tijuana | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Affimed GmbH | For profit | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1